Pentacea (IBC Pharmaceuticals)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePentacea (IBC Pharmaceuticals)

Drug Alias NamePentacea

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment

Mechanisms of ActionAnti-CEA

TargetsCarcinoembryonic antigen

Therapy Area/IndicationsSmall Cell Lung Carcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunomedics Inc

Active IndicationsN/A

Inactive IndicationsSmall Cell Lung Carcinoma

Other Information

ATC CodeN/A